Introduction {#tca12586-sec-0005}
============

There is a rare classification of non‐small cell lung cancer (NSCLC) called primary pulmonary lymphoepithelioma‐like carcinoma (LELC). Until now, \<300 patients have been reported in the worldwide literature, and the majority of these patients were from China.[1](#tca12586-bib-0001){ref-type="ref"} Furthermore, the latest World Health Organization classification of lung tumors was published in 2015. Compared with the 2004 version, the criteria of larger cell cancer had changed greatly, including elimination of primary pulmonary LELC, and reclassification as other and unclassified carcinomas.[2](#tca12586-bib-0002){ref-type="ref"} Since 1999, this distinct entity was included in the World Health Organization classification of lung tumors. However, the exact classification has been debated over the past 17 years. Obviously, the characteristics of this scarce malignant neoplasm still require further elucidation.

In previous retrospective analyses, many scholars paid attention to etiology, clinical characteristics, detection of target genes, prognostic factors, therapeutic strategy, and so on. As a whole, the Epstein--Barr virus‐associated pulmonary carcinoma often occurred in Southeast Asia, in young and non‐smoker individuals, and there was no sexual predilection. Despite a lack of target agent‐sensitive mutations, overexpressed programmed cell death ligand 1 had been observed in this rare population. At the same time, the serum albumin level, the abovementioned programmed cell death ligand 1 expression level, and the pathological stage might be potential prognostic factors, as reported by Chinese scholars.[3](#tca12586-bib-0003){ref-type="ref"}, [4](#tca12586-bib-0004){ref-type="ref"} In addition, as with other NSCLC subtypes, surgical resection was also considered as the preferred treatment for LELC of the lung.[5](#tca12586-bib-0005){ref-type="ref"} However, because of the limited number of resectable cases, the distributed characteristics of lymph nodes (LNs) in radiology and pathology has not been reported.

Thus, in the present large cohort study, our objectives were to document clinical characteristics and prognostic factors in this Epstein--Barr virus‐associated pulmonary carcinoma. Second, we attempt to explore the pattern of LNs metastasis, which might be helpful for surgeons to determine an operative strategy.

Methods {#tca12586-sec-0006}
=======

Patient selection {#tca12586-sec-0007}
-----------------

A total of 132 consecutive patients with primary pulmonary LELC from October 1999 to August 2016 were investigated in our database. All patients were treated at the Sun Yat‐Sen University Cancer Center, Guangzhou, China. Furthermore, written informed consent was signed by all patients on admission to the hospital for the first time. This retrospective analysis was also approved by the Hospital\'s Research Ethics Committee. We restaged the 132 patients based on the seventh edition of the American Joint Committee on Cancer guidelines, and the detailed individual history data were extracted from hospital records.

Originally, all 98 patients who received surgery were retrieved from our database. Then, patients were eligible to be enrolled if they had received a curative R0 resection and had been diagnosed with LELC of the lung with positive Epstein--Barr encoding regions. In addition, patients in the group should be given nasopharyngoscopy, head and neck computed tomography (CT), or positron emission tomography‐CT to indicate no metastasis from nasopharyngeal carcinoma. Second, patients with N1 and N2 LNs resection and mapping with a minimum of three N2 stations sampled or complete LNs dissection as recommended by the National Comprehensive Cancer Network guidelines contributed an essential condition into the group (eliminated five cases).

The patients who met the following criteria were excluded: death within 30 days of operation, occurrence of a second tumor before/after resection (eliminated one case), and loss to follow‐up (eliminated five cases).

In the final data analysis, 87 patients were ultimately included in this cohort study. The clinical and demographic characteristics of the 87 cases of primary pulmonary LELC are shown in Table [1](#tca12586-tbl-0001){ref-type="table-wrap"}.

###### 

Clinical and demographic characteristics of the 87 resectable primary pulmonary lymphoepithelioma‐like carcinoma, and Kaplan--Meier univariate survival analysis for recurrence‐free survival and overall survival

  Variables                 No. of cases, (*n*)   Five‐year RFS (%)   *P* [†](#tca12586-note-0002){ref-type="fn"}   Five‐year OS (%)   *P* [†](#tca12586-note-0002){ref-type="fn"}
  ------------------------ --------------------- ------------------- --------------------------------------------- ------------------ ---------------------------------------------
  Age, years (mean ± SD)       53.07 ± 10.22                                                                                          
  \<60                              68                  66.0                             0.959                            80.8                            0.151
  ≥60                               19                  73.9                             73.7                                         
  Sex                                                                                                                                 
  Female                            44                  73.2                             0.768                            72.9                            0.379
  Male                              43                  63.6                             86.7                                         
  Smoking status                                                                                                                      
  Smokers                           20                  72.6                             0.574                            78.4                            0.693
  Non‐smokers                       67                  57.7                             95.0                                         
  Tumor location                                                                                                                      
  LUL                               14                  49.1                             0.643                            85.7                            0.512
  LLL                               27                  76.4                             91.1                                         
  RUL                                7                  85.7                              100                                         
  RML                               25                  82.7                             54.0                                         
  RLL                               14                  61.7                             54.0                                         
  Neoadjuvant therapy                                                                                                                 
  Yes                                6                  41.7                             0.411                            100                             0.406
  No                                81                   70                              78.9                                         
  Tumor stage                                                                                                                         
  T1                                34                  75.4                             0.866                            71.5                            0.319
  T2                                47                  60.0                             91.1                                         
  T3                                 6                  66.7                             66.7                                         
  Nodal stage                                                                                                                         
  N0                                32                  88.9                             0.000                            88.9                            0.056
  N1                                20                  94.7                             95.0                                         
  N2                                35                  22.3                             62.3                                         
  TNM Stage                                                                                                                           
  I                                 25                  87.5                             0.000                            85.7                            0.057
  II                                27                  96.2                             96.3                                         
  IIIa                              35                  22.3                             62.3                                         
  Adjuvant therapy                                                                                                                    
  Yes                               54                  53.0                             0.005                             80                             0.936
  No                                33                  94.7                             81.3                                         
  Extent of resection                                                                                                                 
  Lobectomy                         67                  68.2                             0.098                            81.2                            0.965
  Biloectomy                         8                  87.5                             85.7                                         
  Pneumonectomy                     12                  55.0                             66.7                                         
  Surgical approach                                                                                                                   
  Open                              70                  72.6                             0.542                            77.5                            0.219
  VATS                              17                  35.9                              100                                         
  LNR                                                                                                                                 
  0%                                31                  88.2                             0.006                            88.9                            0.019
  \>0%,\<30%                        46                  62.1                             90.3                                         
  ≥30%                              10                  28.1                             29.2                                         
  PLNs                                                                                                                                
  0                                 31                  88.2                             0.009                            88.9                            0.004
  1--5                              44                  61.8                             84.6                                         
  ≥5                                12                    0                              35.6                                         
  Recurrence status                                                                                                                   
  Recurrence                        17                   ---                              ---                             82.7                            0.260
  Non‐recurrence                    70                   75                                                                           

The *P*‐value of \<0.05 was regarded as statistically significant.

LLL, left lower lobe; LNR, rate of lymph nodes metastases; LUL, left upper lobe; OS, overall survival; PLNs, the number of positive lymph nodes; RFS, recurrence‐free survival; RML, right middle lobe; RLL, right lower lobe; RUL, right upper lobe; VATS, video‐assisted thoracic surgery.

Computed tomography evaluation of LNs metastasis {#tca12586-sec-0008}
------------------------------------------------

Consensus interpretation of CT scanning was carried out by two board‐certified radiologists independently, and suspicion of malignancy of mediastinal or hilar LNs was recorded based on a short‐axis diameter \>10 mm.

End‐points and follow‐up {#tca12586-sec-0009}
------------------------

The interval of overall survival (OS) was measured from the date of diagnosis to the date of death by any cause or to the date of the last follow‐up day. Recurrence‐free survival (RFS) was defined as the interval from the date of surgical resection to the date of disease recurrence. The following frequencies of follow‐up are recommended by the National Comprehensive Cancer Network guidelines: 3--4 months postoperatively for one year, every six months for three years, and then every year. The chest CT scan with/without contrast was used to monitor recurrence every 6--12 months for 2 years after operation, and every year thereafter. If patients had symptoms, positron emission tomography‐CT or brain magnetic resonance imaging scan was required. In our group, the median follow‐up time was 34 months (range 1 month--156 months), and the last day of follow‐up was 14 September 2016.

Statistical analysis {#tca12586-sec-0010}
--------------------

All statistical analyses were carried out in SPSS 20.0 (IBM, Armonk, NY, USA). The optimal cut‐off values of the number of positive LNs (PLNs) and rate of LNs metastases (LNR) were calculated by Cox proportional hazards regression analysis. Determined using maximal χ^2^ score, the optimal cut‐off values were 0/1--5/≥5 for PLNs (χ^2^ = 8.443, *P* = 0.004) and 0/0--30%/≥30% for LNR (χ^2^ = 5.523, *P* = 0.019).

Survival rates were calculated by the Kaplan--Meier (K‐M) analysis, and were compared by the log--rank test. The χ^2^‐test or Fisher\'s exact test was carried out to test for significance in the probability of comparative variables between two or more groups. Significance was determined as a *P*‐value \<0.05.

Results {#tca12586-sec-0011}
=======

Patient characteristics {#tca12586-sec-0012}
-----------------------

In this retrospective analysis, we found that resected primary pulmonary LELC often occurred in young individuals (78.2%), while the median age at diagnosis was 54 years (range 27--72). Moreover, just 20 patients (23%) were smokers, and the patients with a smoking index ≥400 accounted for 65% (13/20). Furthermore, the proportions of these patients diagnosed at postoperative pathological staging I, II, and IIIa were 28.7%, 31.0%, and 40.2%, respectively.

In these cases, just six pathologically IIIa‐N2 patients received neoadjuvant chemotherapy. After operation, 54 cases were given platinum‐based adjuvant therapy, and four of 54 cases also received adjuvant radiotherapy. The regimens of adjuvant chemotherapy included paclitaxel/docetaxel with cisplatin/carboplatin (28, 51.9%) pemetrexed with cisplatin/carboplatin (18, 33.3%), and gemcitabine with cisplatin/carboplatin (8, 14.8%).

RFS and OS in primary pulmonary LELC {#tca12586-sec-0013}
------------------------------------

In our cohort, the median follow‐up time was 34 months (range 1--156 months), and the last day of follow‐up was 14 September 2016. According to the OS and RFS curves calculated by K‐M analysis, the one‐, two‐, three‐, four‐, and five‐year OS proportions were 97.7%, 96.4%, 93.3%, 90.1%, and 80.3%, respectively; with the corresponding RFS rates of 93.9%, 86.6%, 82.6%, 72.4%, and 67.6%; however, the medians for all OS and RFS for our cohort were not reached at the last follow‐up.

The K‐M method was used to investigate prognostic factors involved in RFS and OS. The variables listed in Table [1](#tca12586-tbl-0001){ref-type="table-wrap"} were analyzed as prognostic factors. Further analysis showed that patients with early pathological stages, without adjuvant therapy, with a LNR and a fewer number of PLNs, and without LNs invasion had better prognosis for RFS. The difference was statistically significant (*P* \< 0.05; Fig [1](#tca12586-fig-0001){ref-type="fig"}a,c,e). Meanwhile, for OS, early pathological stages, a low LNR, and fewer PLNs also revealed relevance with a significantly better prognosis (*P* \< 0.05; Fig [1](#tca12586-fig-0001){ref-type="fig"}b,d,f). Cox proportional hazard regression analysis was carried out to assess for prognostic factors for RFS and OS. Finally, only a more advanced pathological stage was revealed to be independently associated with inferior RFS (*P* = 0.038; Table [2](#tca12586-tbl-0002){ref-type="table-wrap"}).

![(**a**,**b**) Recurrence‐free survival and overall survival curves based on Kaplan--Meier analysis between different pathological stages (I--II/IIIA). (**c**,**d**) Recurrence‐free survival and overall survival curves based on Kaplan--Meier analysis according to positive lymph nodes proportion (0%/0--30%/30%). (**e**,**f**) Recurrence‐free survival and overall survival curves based on Kaplan--Meier analysis according to positive lymph nodes number (0/1--4/≥5).](TCA-9-360-g001){#tca12586-fig-0001}

###### 

Cox multivariate survival analysis for recurrence‐free survival and overall survival of resectable primary pulmonary lymphoepithelioma‐like carcinoma cases

  Variables            Groups                 Recurrence‐free survival   Overall survival                         
  -------------------- --------------------- -------------------------- ------------------ ---------------------- -------
  Age (years)          \<60/≥60                 0.900 (0.234--3.456)          0.878         0.781 (0.431--1.416)   0.416
  Sex                  Female/male              1.809 (0.403--8.109)          0.439         1.622 (0.904--2.912)   0.105
  Smoking status       Smokers/non‐smokers      0.389 (0.066--2.288)          0.296         0.588 (0.298--1.162)   0.126
  Surgical approach    Open/VATS                0.669 (0.188--2.374)          0.534         0.566 (0.321--0.996)   0.084
  Pathological Stage   I--II/IIIa               0.103 (0.012--0.879)          0.038         0.882 (0.452--1.720)   0.713
  Nodal stage          N0/N1--N2               2.156 (0.185--25.111)          0.540         0.943 (0.492--1.807)   0.859
  Adjuvant therapy     Yes/no                  5.419 (0.635--46.247)          0.122         0.757 (0.450--1.276)   0.296
  LNR                  \<30%/≥30%               0.791 (0.183--3.419)          0.754         1.245 (0.408--3.801)   0.701
  PLNs                 \<5/≥5                   0.820 (0.199--3.382)          0.784         0.765 (0.246--2.384)   0.644

The *P*‐value of \<0.05 was regarded as statistically significant.

CI, confidence interval LNR, rate of lymph nodes metastases; PLNs, the number of positive lymph nodes.

LNs staging in radiology {#tca12586-sec-0014}
------------------------

The distribution of LNs staging diagnosed at radiology included stage N0 in 36 patients, stage N1 in 13 patients, stage N2 in 36 patients, and stage N3 in two patients. When compared with postoperative pathological diagnosis, the LNs status was correctly evaluated in 46 patients (46/87, 52.9%) by using CT alone. In these incorrect N staging cases, the majority was upstaged (30/41, 73.2%). In addition, all 411 LNs stations, including 346 mediastinal and 65 hilar, were examined under microscopy. Among them, 68 LNs stations (68/411, 16.5%) in 43 patients were confirmed as invasion by malignant cells, and just eight patients were proven to have multiple mediastinal metastases. However, for malignant LNs depiction using preoperative CT acquisition, 98 LNs stations were suspected of malignancy, and 24 patients were determined to have multiple mediastinal metastases, which was an obviously exaggerated result. Finally, the accuracy and specificity of CT in mediastinal and hilar LNs evaluation were 52.9% (46/87) and 88% (302/343), respectively.

Skipping metastasis {#tca12586-sec-0015}
-------------------

Up to 25 of 35 N2 cases (71.4%) showed skipping metastasis. By contrastive analysis, the average number of resected MLNs or ILNs did not differ between the skipping and non‐skipping group (*P* = 0.341). In addition, five cases with pathological N2 stage in LUL all showed skipping metastasis, followed by right lower lobe (RLL; 5/6, 83.3%), left upper lobe (LLL; 9/12, 75%), right upper lobe (RUL; 1/2, 50%), and right middle lobe (RML; 5/10, 50%). There was no statistically significant difference in the rate of skipping metastasis between upper lobes and lower lobes (*P* = 0.656), and this comparison between left and right lobes yielded the same result (*P* = 0.264). In addition, whether or not those patients showed skipping metastasis did not affect their RFS or OS (*P* = 0.438 and 0.971, respectively).

Distribution of invaded LNs based on different lobes {#tca12586-sec-0016}
----------------------------------------------------

In the 14 cases with a tumor located in LUL, if concomitant superior mediastinal LNs involvement was not found, there was almost no inferior mediastinal LNs metastasis (0.0%). Similarly, if concomitant hilar or inferior mediastinal LNs invasion was not present, the primary tumor located in LLL rarely metastasized to superior mediastinal LNs (1/27, 3.7%). Based on the above phenomenon, we found that the rate of inferior mediastinal nodes invasion in patients with tumors located in LLL was significantly higher than that of patients with tumors located in LUL (*P* = 0.015). Similarly, compared with patients who had tumors located in LLL, patients who had tumors located in LUL showed a higher metastatic frequency (*P* = 0.012) in aortic nodes (Tables [3](#tca12586-tbl-0003){ref-type="table-wrap"} and [4](#tca12586-tbl-0004){ref-type="table-wrap"}).

###### 

Number of patients with positive lymph nodes according to different lobes

  Locations of lymph nodes       LUL (*n* = 14)   LLL (*n* = 27)   RUL (*n* = 7)   RML (*n* = 25)   RLL (*n* = 14)
  ----------------------------- ---------------- ---------------- --------------- ---------------- ----------------
  2\. Upper paratracheal              ---              ---           2 (28.6%)        2 (8.0%)         0 (0.0%)
  3.Prevascular/retrotracheal         ---              ---           0 (0.0%)        3 (12.0%)         0 (0.0%)
  4\. Lower paratracheal            1 (7.1%)         2 (7.4%)        1 (14.3%)       4 (16.0%)         0 (0.0%)
  5\. Subaortic                    3 (21.4%)         0 (0.0%)           ---             ---              ---
  6\. Para‐aortic                   0 (0.0%)         0 (0.0%)           ---             ---              ---
  7\. Subcarinal                    1 (7.1%)        11 (40.7%)       0 (0.0%)        7 (28.0%)        6 (42.9%)
  8\. Paraesophageal                0 (0.0%)         1 (3.7%)        0 (0.0%)         1 (4.0%)         0 (0.0%)
  9\. Pulmonary ligament            0 (0.0%)        3 (11.1%)        0 (0.0%)         5 (2.0%)        2 (14.3%)
  10\. Hilar                       1 (7.1%))        5 (18.5%)        1 (0.0%)         5 (2.0%)         1 (7.1%)
  11\. Interlobar                  4 (28.6%)        10 (37.0%)       0 (0.0%)        3 (12.0%)        5 (35.7%)
  12\. Lobar                       4 (28.6%)         2 (7.4%)        1 (14.3%)        2 (8.0%)        3 (21.4%)
  13\. Segmental                    1 (7.1%)        4 (14.8%)        1 (14.3%)        0 (0.0%)         0 (0.0%)
  14\. Subsegmental                   ---            1 (3.7%)           ---             ---              ---

LLL, left lower lobe; LUL, left upper lobe; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe.

###### 

Distributions of invaded lymph nodes compared with different lobes

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stations                 LUL vs. LLL (*P*‐value[†](#tca12586-note-0008){ref-type="fn"})   RUL vs. RML (*P*‐value[†](#tca12586-note-0008){ref-type="fn"})   RML vs. RLL (*P*‐value[†](#tca12586-note-0008){ref-type="fn"})   RUL vs. RLL (*P*‐value[†](#tca12586-note-0008){ref-type="fn"})
  ----------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------
  Superior MLNs\                               1 (7.1%) vs. 2 (7.4%)\                                          2 (28.6%) vs. 7 (28.0%)\                                         7 (28.0%) vs. 0 (0.0%)\                                          2 (28.6%) vs. 0 (0.0%)\
  (station 2--4)                                       0.975                                                            0.976                                                            0.029                                                            0.100

  Aortic nodes\                               3 (21.4%) vs. 0 (0.0%)\                                                    ---                                                              ---                                                              ---
  (station 5--6)                                       0.012                                                                                                                                                                 

  Inferior MLNs\                              1 (7.7%) vs. 12 (42.3%)\                                         0 (0.0%) vs. 7 (28.0%)\                                          7 (28.0%) vs. 6 (42.9%)\                                         0 (0.0%) vs. 6 (42.9%)\
  (station 7--9)                                       0.015                                                            0.113                                                            0.345                                                            0.061

  Intrapulmonary nodes\                      8 (61.5%) vs. 16 (57.7%)\                                         2 (28.6%) vs. 9 (36.0%)\                                         9 (36.0%) vs. 5 (35.7%)\                                         2 (28.6%) vs. 5 (35.7%)\
  (station 10--14)                                     0.896                                                            0.715                                                            0.419                                                            0.743
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The *P*‐value \<0.05 was regarded as statistically significant.

LLL, left lower lobe; LUL, left upper lobe; RML, right middle lobe; RLL, right lower lobe; RUL, right upper lobe.

In the right lobes, the points and characteristics of the upper and lower lobes were extremely similar to the corresponding left lobes. It might be deduced that the paratracheal nodes (3 cases) and the seven‐station (6 cases) were the RUL‐ and RLL‐specific patterns of LNs involvement, respectively. In the 25 cases with the tumor located in RML, the distribution of patients with malignant nodes seemed to be evenly distributed between intrapulmonary, hilar, subcarinal, and superior mediastinal nodes. The seven‐station (7 cases) and superior mediastinal nodes might be considered as the RML‐specific pattern of LNs involvement. In addition, only tumors located in the RML had a greater risk for metastases to the upper mediastinal LNs than those in RLL (*P* = 0.029; Tables [3](#tca12586-tbl-0003){ref-type="table-wrap"}, [4](#tca12586-tbl-0004){ref-type="table-wrap"}).

Generally, the sentinel nodes are intrapulmonary and found in the 11‐station (22 cases), 10‐station (13 cases), and 12‐station (12 cases) regardless of primary tumor location. Route dissection of these stations may not be omitted.

Discussion {#tca12586-sec-0017}
==========

In contrast with other subtypes of lung cancer, all results showed that LELC of the lung had a better prognosis.[3](#tca12586-bib-0003){ref-type="ref"}, [6](#tca12586-bib-0006){ref-type="ref"}, [7](#tca12586-bib-0007){ref-type="ref"}, [8](#tca12586-bib-0008){ref-type="ref"} Similarly, the above tendency was also obtained from our study. In 87 resectable cases, the five‐year OS and RFS rates were 78.9% and 70.0%, respectively, which were slightly higher than the rates found in a previous review.[7](#tca12586-bib-0007){ref-type="ref"} Among our resectable LELC of the lung cases, the K‐M method showed that cases with pathological stages I--II had a better prognosis for RFS and OS than those with stage IIIa (*P* \< 0.000 and 0.017, respectively). Furthermore, patients with LNs involvement had significantly inferior RFS (*P* = 0.011). For all patients who received radical surgery, adjuvant therapy (CT ± RT) did not improve their RFS (*P* = 0.005), even in pathological stage IIIa, which was the exact opposite of a finding by Liang *et al.* ^3^ Then, through Cox multivariate survival analysis, only pathological stage (I--II vs. IIIa) was confirmed to be an independent prognostic factor for RFS, which was completely consistent with Li Jiang\'s report.[7](#tca12586-bib-0007){ref-type="ref"} In brief, the comprehensive stage for primary pulmonary LELC based on TNM standard has a better clinical application value as a risk factor for RFS.

In addition, in previous reports, the LNs of primary LELC of the lung appeared larger than other subtypes of NSCLC radiologically, and suspicion of LNs invasion by malignant cells was common based on radiological signs (100% by Ooi, 81.3% by Huang, 68.3% by Ma).[9](#tca12586-bib-0009){ref-type="ref"}, [10](#tca12586-bib-0010){ref-type="ref"}, [11](#tca12586-bib-0011){ref-type="ref"} However, due to a lack of pathological confirmation, the sensitivity and specificity of the evaluation of LNs by using radiology alone could not draw a definite conclusion. In our cohort, 30 LNs groups were misdiagnosed as positive at CT scanning (98 groups at radiology vs. 68 groups at pathology), and 16 patients were misclassified as having multiple mediastinal metastases (24 patients at radiology vs. 8 patients at pathology), which was an obviously exaggerated result. Thus, regarding the enlarged LNs observed by radiology, positron emission tomography‐CT scanning, endobronchial ultrasonography‐guided transbronchial needle aspiration, or endoscopic ultrasonography guided fine needle aspiration was used for re‐evaluation to avoid missing an operation chance.

The current eighth edition of NSCLC regarded LNs staging as a creditable prognostic factor, and LNs staging is based on the location of invaded LNs regardless of the number of PLNs.[12](#tca12586-bib-0012){ref-type="ref"} However, the updated pathological TNM stage of colorectal and breast cancer had deemed PLNs as novel criteria.[13](#tca12586-bib-0013){ref-type="ref"} According to several retrospective studies on NSCLC from 2006 to now, PLNs had been discovered to possibly be a better prognostic factor than station‐based LNs staging.[14](#tca12586-bib-0014){ref-type="ref"}, [15](#tca12586-bib-0015){ref-type="ref"}, [16](#tca12586-bib-0016){ref-type="ref"} In another retrospective study, the LNRs had shown more valuable independent prognostic features.[17](#tca12586-bib-0017){ref-type="ref"} In our cohort, efforts were also made to explore the prognostic value of PLNs and LNR in LELC of the lung. Through K‐M analysis, a higher PLN (≥30%) and LNP (≥5) indicated inferior RFS and OS. Specifically, in OS, these two criteria had superiority when compared with LNs staging. Unfortunately, through multivariate analysis, PLNs, LNR, and LNs staging all lost significant prognostic value for this rare NSCLC subtype.

Several studies have tried to explore the involvement pattern in lung cancer based on tumor location. Naruke *et al.* had explored common metastasis lesions of tumors located in RUL and RLL in 1999, and the distributions of major lesions according to each lobe were as follows: \#5‐LUL, \#7‐LLL, \#3 and/or \#4‐RUL, \#3‐RML, and \#7‐RLL.[18](#tca12586-bib-0018){ref-type="ref"} A recent retrospective study carried out by Guo *et al.* also aimed to explore the distribution of MLNs metastases associated with different primary location, and the highest metastasis frequencies for each lobe were as follows: \#5‐LUL, \#7‐LLL, \#2 and/or \#4‐RUL, \#7‐RML, and RLL.[19](#tca12586-bib-0019){ref-type="ref"} In 2006, Yukinori *et al.* proposed that 71.4% patients had metastasis to aortic nodes (the 5 and 6 stations) when the tumor was located in LUL. Furthermore, multivariate analysis determined that only aortic nodal involvement was a significant prognostic factor.[20](#tca12586-bib-0020){ref-type="ref"} With regard to RML with primary tumor, the superior mediastinal zones (\#2--4) and subcarinal zones (\#7) were the most frequent sites for metastasis. In addition, LNs dissection had greater therapeutic value for the abovementioned zones, as confirmed by Kuroda *et al.* [21](#tca12586-bib-0021){ref-type="ref"} The MLNs invaded with high frequency were known as sentinel nodes, and researchers state that if the sentinel MLNs were not invaded, radical systematic dissection can be omitted. The drainage path of the pulmonary LELC is also close to the above results. The highest metastasis frequencies for specific lobes with primary LELC in our 87 cases are as follows: \#5‐LUL (21.4%); \#7‐LLL (40.7%); \#2R (28.6%) and/or \#4R (14.3%)‐RUL; \#7 (42.9%)‐RLL; \#7 (28%) and/or superior mediastinal nodes (36%)‐RML.

There are some limitations to this retrospective analysis. First, as in previous reports, our research cohort was also limited by the scant number of cases, and the majority of the enrolled cases came from South China. Second, the time interval of the study of the patients who were enrolled was from October 1999 to August 2016 (17 years). During this long period, the surgical procedures, the resected range of LNs, the choice of adjuvant chemotherapy, and other factors might have changed; thus, potential selection bias may be unavoidable.

In conclusion, our study is limited by the number of cases and treatment standards for primary LELC of the lung. Pathological N stage, PLNs, LNR, and skipping metastases had not yet been confirmed to be independent predictive factors in our cohort. In addition, in terms of technical aspects, the morbidity or mortality of patients receiving radical MLNs dissection did not increase. Therefore, based on accurate staging and uncertain survival benefit, complete MLNs dissection is still required for curative resection in LELC of the lung.
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